Homing in on New Anticancer Targets

Cancers are diverse and adaptable. That is why a staggering 97% of cancer drugs in clinical trials fail to receive FDA approval. Researchers try to stay one step ahead of cancer by studying the mechanisms that lead to drug resistance, finding new drug targets, and developing novel therapies, such as immunotherapeutics. In this episode narrated by Niki Spahich, Sejal Davla from The Scientist’s Creative Services team spoke with Jason Sheltzer, an assistant professor in the Department of Genomics, Genetics, and Epigenomics and Yale Cancer Center at the Yale School of Medicine, about his work on drug resistance in cancer, chromosomal instability in cancer cells, and approaches to identify new treatment strategies.

More on this topic

A Game of Cancer and Evolution

A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors

The Scientist Speaks is a podcast produced by The Scientist’s Creative Services team. Our podcast is by scientists and for scientists. Once a month, we bring you the stories behind news-worthy molecular biology research. This month's episode is sponsored by Isoplexis, DeNovix, Bio-Rad, and ACROBiosystems.


Jason Sheltzer, PhD
Assistant Professor
Department of Genomics, Genetics, and Epigenomics
Yale Cancer Center
Yale School of Medicine

Sponsored by
IsoPlexis is a life science technology company that accelerates the development of curative medicines and precision therapeutics. Their award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise therapies. Visit http://www.isoplexis.com to learn more.

DeNovix Inc. develops, manufactures, and sells award-winning laboratory equipment for life science applications. Their stand-alone systems include DS-11 Series 1 μL UV-Vis Spectrophotometers / Fluorometers and CellDrop™ Automated Cell Counters for cell counting without slides.
Bio-Rad offers unrivaled precision and absolute quantification of target DNA or RNA molecules. Their unique Droplet Digital PCR technology partitions samples into thousands of microfluidic “droplet” test tubes, providing extremely sensitive and accurate digital answers for life science research, clinical diagnostics, as well as environmental monitoring and food safety testing.


ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of biomedicine, especially cell therapy and antibody drugs. They developed a comprehensive series of more than 50 CAR T target proteins, including the Star Staining fluorescent-labeled targets—solid and blood tumor targets that are specially designed for the evaluation of CAR expression.

Listen Now

TS_Podcast_TSS_September 2021_Homing in on New Anticancer Targets

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this podcast. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these podcasts free of charge for our readers.